跳至主要内容
临床试验/NCT00568412
NCT00568412已完成4 期

A Multicenter, Randomized, Double-blind Clinical Study to Examine the Efficacy and Safety of Zarzenda in Comparison to Elidel in the Management of Mild to Moderate Atopic Dermatitis in Children and Adolescents

Bayer1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2007年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Bayer
入组人数
80
试验地点
1
主要终点
Investigator's Global Assessment

研究概览

简要总结

To show therapeutic efficacy of Zarzenda cream compared to Elidel cream in children and adolescents with mild to moderate atopic dermatitis

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
2 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • male and female children and adolescents (aged 2 - 17)
  • mild to moderate atopic dermatitis
  • patients in whom a treatment with topical corticosteroids in not recommended or possible
  • wash out periods to be observed

排除标准

  • known allergy to one of the two treatments
  • known immunodeficiency
  • known hepatic or renal insufficiency
  • acute skin infections

研究组 & 干预措施

1

Active Comparator

Zarzenda applied topically twice daily for three weeks

干预措施: Zarzenda (Device)

2

Active Comparator

Elidel 1% cream, applied topically twice daily for three weeks

干预措施: Elidel (Drug)

结局指标

主要结局

Investigator's Global Assessment

时间窗: End of study compared to baseline

次要结局

  • Affected body surface area(End of study compared to baseline)
  • Children's Dermatological Life Quality Index(End of study compared to baseline)
  • EASI(End of study compared to baseline)
  • Patient's assessment of itch, quality of sleep, and global assessment(End of study compared to baseline)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验